Cargando…

TRLS-02. FEASIBILITY OF EVALUATING ABEMACICLIB NEUROPHARMACOKINETICS OF DIFFUSE MIDLINE GLIOMA USING INTRATUMORAL MICRODIALYSIS

BACKGROUND: Diffuse midline gliomas (DMG) are the most aggressive brain tumors of childhood and young adults, with documented 2-year survival rates <10%. Treatment failure is due in part to the function of the BBB. Intratumoral microdialysis sampling is an effective tool to determine brain entry...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jackson, Sadhana, Glod, John, Peer, Cody, Figg, William, Dalmage, Mahalia, Brown, Desmond
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Final Category: Translational Therapeutics/Clinical Trials - TRLS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260119/ http://dx.doi.org/10.1093/neuonc/noad073.305

Ejemplares similares

Clinical protocol: Feasibility of evaluating abemaciclib neuropharmacokinetics of diffuse midline glioma using intratumoral microdialysis
por: Nduom, Edjah K., et al.
Publicado: (2023)

CLRM-05 FEASIBILITY OF EVALUATING ABEMACICLIB NEUROPHARMACOKINETICS OF DIFFUSE MIDLINE GLIOMA USING INTRATUMORAL MICRODIALYSIS
por: Dalmage, Mahalia, et al.
Publicado: (2022)

TRLS-06. A PHASE 1, SAFETY AND DOSE ESCALATION STUDY OF BXQ-350 IN COMBINATION WITH RADIATION IN PEDIATRIC PATIENTS WITH DIFFUSE MIDLINE GLIOMA OR DIFFUSE INTRINSIC PONTINE GLIOMA
por: Dorris, Kathleen, et al.
Publicado: (2023)

TRLS-03. IBRUTINIB DISRUPTS BLOOD-TUMOR BARRIER INTEGRITY TO ENHANCE CNS DRUG DELIVERY AND RODENT GLIOMA MODEL SURVIVAL
por: Lim, Sanghee, et al.
Publicado: (2023)

TRLS-16. RAPID GENERATION OF EPENDYMOMA MOUSE MODELS FOR PRE-CLINICAL STUDIES
por: Ippagunta, Siri, et al.
Publicado: (2023)

TRLS-04. PRECLINICAL VALIDATION OF A NOVEL THERAPEUTIC STRATEGY FOR CHOROID PLEXUS CARCINOMA
por: Martin, Brice, et al.
Publicado: (2023)

TRLS-14. TARGETING REPLICATIVE STRESS IN BRAIN TUMORS BY COMBINING ATR AND PARP INHIBITION
por: Sarvode, Supriya, et al.
Publicado: (2023)

TRLS-15. TARGETED THERAPY IN PEDIATRIC CNS TUMORS - A SINGLE INSTITUTION EXPERIENCE
por: Olsen, Braden, et al.
Publicado: (2023)

TRLS-09. USE OF A PAN-PEPTIDE CHECKPOINT INHIBITOR IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM TUMORS
por: Moertel, Christopher, et al.
Publicado: (2023)

TRLS-08. EXPERIENCE WITH THE SELECTIVE FIBROBLAST GROWTH FACTOR INHIBITOR ERDAFITINIB IN THREE PEDIATRIC PATIENTS WITH CNS TUMORS
por: Stepien, Natalia, et al.
Publicado: (2023)

TRLS-01. FDA ANALYSIS OF EXPANDED ACCESS USE IN PEDIATRIC PATIENTS WITH CNS TUMORS FROM 2015 TO 2020
por: Duke, Elizabeth, et al.
Publicado: (2023)

TRLS-10. ROVER: A PHASE 1/2 STUDY OF AVAPRITINIB IN PEDIATRIC PATIENTS WITH SOLID TUMORS DEPENDENT ON KIT OR PDGFRA SIGNALING
por: Koschmann, Carl, et al.
Publicado: (2023)

TRLS-13. NOVEL PAN-RAF INHIBITOR BELVARAFENIB AS A PROMISING TARGETED THERAPY FOR BRAF-ALTERED PEDIATRIC LOW-GRADE GLIOMAS
por: Gonzalez, Maxine, et al.
Publicado: (2023)

TRLS-12. INTRAVENTRICULAR B7-H3 CAR T CELLS FOR DIFFUSE INTRINSIC PONTINE GLIOMA: INTERIM ANALYSIS OF BRAINCHILD-03 ARM C
por: Vitanza, Nicholas, et al.
Publicado: (2023)

TRLS-07. GLOBAL POST-MARKETING SURVEILLANCE DATA FROM PEDIATRIC AND ADULT PATIENTS WITH CENTRAL NERVOUS SYSTEM MALIGNANCIES TREATED WITH TUMOR TREATING FIELDS (TTFIELDS) THERAPY BETWEEN 2011–2022
por: Mrugala, Maciej M, et al.
Publicado: (2023)

TRLS-05. PRELIMINARY RESULTS FROM A PHASE I TRIAL TO EVALUATE INTRAVENTRICULAR DELIVERY OF IL13RΑ2-TARGETING CAR T CELLS AFTER LYMPHODEPLETION IN PEDIATRIC BRAIN TUMORS PATIENTS
por: Davidson, Tom, et al.
Publicado: (2023)

TRLS-11. A PHASE 1 STUDY OF SAVOLITINIB IN RECURRENT, PROGRESSIVE, OR REFRACTORY MEDULLOBLASTOMA, HIGH-GRADE GLIOMA, DIFFUSE INTRINSIC PONTINE GLIOMA, AND CENTRAL NERVOUS SYSTEM (CNS) TUMORS HARBORING MET ABERRATIONS: A PEDIATRIC BRAIN TUMOR CONSORTIUM TRIAL
por: Salloum, Ralph, et al.
Publicado: (2023)

CNSC-03. EXPLORING STRUCTURAL DISRUPTION OF TRICELLULAR JUNCTIONS TO ENHANCE BLOOD-BRAIN-BARRIER PERMEABILITY
por: Cesaire, Melissa, et al.
Publicado: (2023)

PAEDIATRIC-02 ROLE OF INTRAOPERATIVE INTRATUMORAL HYDROGEN PEROXIDE IN RESECTION OF SOLID BRAIN TUMORS: CASE SERIES AND BRIEF REVIEW OF LITERATURE
por: Lubuulwa, James, et al.
Publicado: (2023)

OTHER-02 BRAIN TUMORS: CLINICAL PRESENTATION AT THE NATIONAL CENTER FOR NEUROLOGICAL SCIENCES IN KHARTOUM 2019-2022
por: Nasr, Arwa, et al.
Publicado: (2023)

MENINGIOMA-02 A RADIOLOGY- PATHOLOGICAL CORRELATION OF HYPEROSTOSIS AMONG PATIENTS WITH INTRACRANIAL MENINGIOMAS AT THE KENYATTA NATIONAL HOSPITAL.
por: Marjorie, Adagi, et al.
Publicado: (2023)

GLIOMA-02 HISTOPATHOLOGIC AND MOLECULAR PROFILE OF GLIOMAS: A 9-YEAR RETROSPECTIVE STUDY OF CASES DIAGNOSED IN LAGOS NIGERIA
por: Odukoya, Lateef, et al.
Publicado: (2023)

NEIM-02 CHARACTERIZATION OF LARGE BRAIN METASTASES WITH(18)F-FLUCICLOVINE PET/CT TREATED WITH STAGED STEREOTACTIC RADIOSURGERY (SSRS): INTERIM ANALYSIS OF A PILOT STUDY
por: Rosa, Alonso La, et al.
Publicado: (2023)

EPEN-11. CHARACTERIZATION OF THE SPATIAL ARCHITECTURE OF INTRATUMORAL CELL STATES IN PEDIATRIC HIGH-RISK EPENDYMOMA
por: Bruckner, Katharina, et al.
Publicado: (2023)

CNSC-02. INVESTIGATING THE ROLE OF THE WNT SIGNALING TRANSDUCTION PATHWAY IN GLIOMA BLOOD-BRAIN-BARRIER INTEGRITY
por: Tang, Kayen, et al.
Publicado: (2023)

CNSC-01. GABAERGIC NEURON-TO-GLIOMA SYNAPSES IN DIFFUSE MIDLINE GLIOMAS
por: Barron, Tara, et al.
Publicado: (2023)

IMG-02. VISUALIZATION OF TIGIT IN THE GLIOMA MICROENVIRONMENT: THE CREATION OF A PET IMAGING TRACER
por: Frederico, Stephen, et al.
Publicado: (2023)

IMMU-06. SYSTEMIC MRNA VACCINES RESET IMMUNOGENICITY AGAINST DIFFUSE MIDLINE GLIOMA
por: McGuiness, James, et al.
Publicado: (2023)

PATIENT ADVOCACY-02 BRAIN TUMORS MATTER: HOW TO IMPROVE THE MANAGEMENT OF PATIENTS WITH BRAIN TUMORS AT THE CNHU HKM OF COTONOU IN BENIN?
por: Gankpe, Gbetoho Fortune
Publicado: (2023)

EPEN-02. OPTIMISING BIOMARKERS FOR ACCURATE EPENDYMOMA DIAGNOSIS, PROGNOSTICATION AND STRATIFICATION WITHIN INTERNATIONAL CLINICAL TRIALS: A BIOMECA STUDY
por: Chapman, Rebecca J, et al.
Publicado: (2023)

MDB-02. NUCLEAR ENVELOPE PHOSPHATASE CTDNEP1 MUTATIONS POTENTIATE AGGRESSIVE MEDULLOBLASTOMA BY TRIGGERING MYC ACTIVATION AND GENOMIC INSTABILITY
por: Lu, Richard, et al.
Publicado: (2023)

OTHER-04 FEASIBILITY STUDY ON BRAIN TUMOR BIOBANKING AND REGISTRY IN SUB-SAHARAN AFRICAN COUNTRIES: A QUESTIONNAIRE-BASED SURVEY
por: Odukoya, Lateef, et al.
Publicado: (2023)

TIPS-12 PHASE I CLINICAL STUDY OF TG02 CAPSULE IN THE TREATMENT OF RECURRENT HIGH-GRADE GLIOMAS WITH FAILED TMZ TREATMENT
por: Guo, Chengcheng, et al.
Publicado: (2023)

PITUITARY TUMORS-02 EVOLUTION OF PITUITARY SURGERIES TO THE TRANS-SPHENOIDAL APPROACH IN A NIGERIAN TEACHING HOSPITAL: LEANING ON LOCAL TRANSFER OF SKILLS
por: Balogun, Simon, et al.
Publicado: (2023)

IMMU-18. TARGETING GD2 IN THALAMIC DIFFUSE MIDLINE GLIOMA WITH TRANSIENT MRNA CAR T CELLS
por: Foster, Jessica, et al.
Publicado: (2023)

IMMU-02. CMV-EXPANDED T-CELLS IN GLIOBLASTOMA PATIENTS: TRANSLATIONAL RESEARCH
por: Kampers, Linde F C, et al.
Publicado: (2023)

TRANSLATIONAL RESEARCH-02 THE KEYSTONE CYTOKINE, INTERLEUKIN-6, A KEY TARGET AND “ORGANIZING PRINCIPLE” FOR GLIOBLASTOMA THERAPY: A DECADE OF TRANSLATIONAL PROGRESS FROM GENOMICS TO THE LABORATORY AND TO A MULTICENTER CLINICAL TRIAL
por: Brem, Steven
Publicado: (2023)

DIPG-02. A NOVEL STRATEGY TO RADIOSENSITISE DIFFUSE MIDLINE GLIOMAS VIA DUAL-TARGETING OF GLUCOSE METABOLISM
por: Shen, Han, et al.
Publicado: (2023)

NEIM-14 PET/MRI DETECTS A RAPID DECREASE IN CEREBRAL BLOOD FLOW IN GLIOBLASTOMA FOLLOWING BEVACIZUMAB INFUSION
por: Thaw-Poon, Serena, et al.
Publicado: (2023)

NEIM-03 A GRADUAL INTEGRATION MODEL BASED ON MRI TO PREDICT MOLECULAR PROFILES IN PATIENTS WITH GLIOMA
por: Chen, Hongyu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1nup526sc8r9orn51q6p8gd259